Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2000-03-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The rate of erectile dysfunction in men who receive a prolonged period of Gosereline (i.e. 2 yrs) is not known, but suspected according to expert opinion, to be significantly higher than a shorter course of hormonal ablation. Therefore the price of of a survival advantage in locally advanced prostate cancer maybe at a cost of increased rates of erectile dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
NCT00002889
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
NCT02229734
REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
NCT07302451
Proton Therapy for Low and Intermediate Risk Prostate Cancer
NCT00693238
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
NCT04249154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erectile Dysfunction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have undergone radical radiation and at least 2 years of Pharmacological androgen ablation.Pharmacological androgen ablation may include: LHRH-agonists with or without Non-steroidal androgen ablation, Steroidal Anti-androgens, Progestational agents, and Cypoterone (Androcur).
* Must be currently 6 months or more after their last injection of LHRH-agonists if it was being given every 3 months or 4 months or more after their last injection, if it was being given monthly. If the patient was on oral androgen ablation agent, they must be off this medication for a period of at least 4 months.
* currently off hormonal therapy
* Able to sign the consent form and fill out questionnaire used in the study.
Exclusion Criteria
* no previous orchidectomy.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Princess Margaret Hospital, Canada
OTHER
University Health Network, Toronto
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Padraig Warde, MD
Role: PRINCIPAL_INVESTIGATOR
Princess Margaret Hospital, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network Princess Margaret Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHN REB 01-0552-C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.